While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.
Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in ...